Premium
No signs of Campylobacter jejuni/coli ‐related antibodies in patients with active ankylosing spondylitis
Author(s) -
Andreasen JAN JESPER,
Ringsdal VIBEKE STEVENIUS,
Helin PEKKA
Publication year - 1991
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1699-0463.1991.tb01252.x
Subject(s) - ankylosing spondylitis , campylobacter jejuni , campylobacter , sulfasalazine , medicine , antibody , immunology , pathogenesis , titer , immunoglobulin a , spondylitis , immunoglobulin m , antibody titer , gastroenterology , immunoglobulin g , biology , bacteria , disease , ulcerative colitis , genetics
Twenty‐two patients with active ankylosing spondylitis were investigated to assess the levels of specific serum IgG, IgA and IgM titres against Campylobacter jejunil coli before and during treatment with sulfasalazine. An enzyme‐linked immunosorbent assay was used, and the results were compared with the antibody levels in 300 healthy blood donors. Three patients had elevated levels of serum anti‐Campylobacter‐IgA before treatment, and a two‐fold decrease in the antibody titre was observed during treatment. Three patients had elevated anti‐Campylobacter‐IgG titres before treatment. One of these patients also had elevated anti‐Campylobacter‐IgA and IgM titres. Elevated IgM titres were not seen in any other patient. The results do not support the hypothesis that C. jejunilcoli plays an important role in the pathogenesis of active AS.